Abstract
Recent evidence suggests the existence of a diversity of neuronal nicotinic acetylcholine receptor (nAChRs) subtypes with a wide distribution in brain, that each subtype may be involved in mediating specific functions/behaviors, and that these subtypes have a defined pharmacology that may be selectively targeted (Arnerić et al., 1995a). The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favorable side-effect profiles than existing agents which generally exhibit low selectivity. This broader class of agents, collectively called cholinergic channel modulators (ChCMs) selectively activate some subtypes of nAChRs (i.e. Cholinergic Channel Activators, ChCAs) or inhibit the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnerić SP, Holladay MW, and Sullivan JP (1996): Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer’s disease. Exp. Opin. Invest. Drugs 5(1): 79–100.
Arnerić SP, Sullivan JP and Williams M (1995a): Neuronal nicotinic acetylcholine receptors: novel targets for CNS therapeutics. In: Psychopharmacology: 4th Generation of Progress, Bloom F.E. and Kupfer DJ, eds., New York, Raven Press; pp. 94–110.
Arnerić SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Decker MW, Brioni JD, Marsh KC, and Rodrigues AD (1995b): Preclinical pharmacology of ABT-418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer’s disease CNS Drug Rev. 1: 1–26.
Donnelly-Roberts DL, Xue I, Arneric SP and Sullivan JP (1996): In vitro neuroprotective properties of the novel cholinergic channel activator (CA), ABT-418. Brain Res. (In press).
Lin N-H., Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Sullivan JP, Williams M, Arnerić SP, and Holladay MW (1996): Structure-Activity Studies on ABT-089: An orally bioavailable 3-pyridyl ether cholinergic channel modulator with cognitive enhancing properties and improved safely profile. J Med Chem. (In press).
Newhouse P, Potter A, and Corwin J (1996): Acute administration of the cholinergic channel activator ABT-418 improves learning in Alzheimer’s disease. SRNT 2nd Annual Conference, Washington, D.C., March 16.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Birkhäuser Boston
About this chapter
Cite this chapter
Arnerić, S.P. et al. (1997). ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action. In: Becker, R.E., Giacobini, E., Barton, J.M., Brown, M. (eds) Alzheimer Disease. Advances in Alzheimer Disease Therapy. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4116-4_42
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4116-4_42
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-8660-8
Online ISBN: 978-1-4612-4116-4
eBook Packages: Springer Book Archive